CJEU ruling to liberalise parallel import in Poland
Biologics and biosimilars litigation update
Return to work: key issues for life sciences
von Helen Farr und Adrian Toutoungi
Private equity investment in life sciences sector
Exploring some of the potential benefits and challenges for life sciences companies considering PE investment.
von mehreren Autoren
4 von 6 Insights
Licensing out: Try not to get benched
von Colin McCall und Justyna Ostrowska
Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents
von mehreren Autoren
IP: Licensing and insolvency
von mehreren Autoren
UK increases scrutiny of tech and life sciences deals
Mergers and acquisitions in the tech and life sciences sectors may be subject to closer scrutiny by the UK competition authority and by the UK government in future.
von Paolo Palmigiano
6 von 6 Insights
US buys up entire stock of remdesivir
Time to intervene?
Arbitration for life sciences companies
von mehreren Autoren
Legal advice privilege: where are we now?
von Georgina Jones